Ipratropium
Showing 1 - 25 of 263
COPD Trial (Ipratropium / Levosalbutamol Fixed Dose Combination, Ipratropium + Levosalbutamol Free Dose Combination)
Not yet recruiting
- COPD
- Ipratropium / Levosalbutamol Fixed Dose Combination
- Ipratropium + Levosalbutamol Free Dose Combination
- (no location specified)
Sep 13, 2023
COPD Trial (Ipratropium / Levosalbutamol Fixed Dose Combination, Ipratropium + Levosalbutamol Free Dose Combination)
Not yet recruiting
- COPD
- Ipratropium / Levosalbutamol Fixed Dose Combination
- Ipratropium + Levosalbutamol Free Dose Combination
- (no location specified)
Jun 5, 2023
COPD Trial in Guangzhou (compound ipratropium bromide solution (3mg salbutamol and 500µg ipratropium, Boehringer Ingelheim
Recruiting
- Chronic Obstructive Pulmonary Disease
- compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)
-
Guangzhou, Guangdong, China1State Key Laboratory of Respiratory Disease, National clinical
Mar 15, 2023
Asthma in Children Trial in Buffalo, Charlotte, Salt Lake City (Ipratropium Bromide)
Not yet recruiting
- Asthma in Children
- Ipratropium Bromide
-
Buffalo, New York
- +2 more
Oct 5, 2023
COPD Trial (Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI, Salbutamol 100 mcg Inhaler (2
Withdrawn
- Chronic Obstructive Pulmonary Disease
- Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI
- Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI
- (no location specified)
Sep 3, 2021
COPD, Acute Respiratory Failure Trial in Los Angeles, Santa Monica (Revefenacin Inhalation Solution [Yupelri], Ipratropium
Recruiting
- COPD
- Acute Respiratory Failure
- Revefenacin Inhalation Solution [Yupelri]
- Ipratropium Bromide
-
Los Angeles, California
- +1 more
Sep 3, 2022
Asthma in Children, Dyspnea; Asthmatic, Obesity, Childhood Trial in Columbus (Control, Albuterol, Ipratropium Bromide)
Not yet recruiting
- Asthma in Children
- +2 more
- Control
- +2 more
-
Columbus, OhioThe Ohio State University
Jul 8, 2022
COPD Exacerbation Trial in Knoxville (Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol
Recruiting
- COPD Exacerbation
- Revefenacin (YUPELRI) & Formoterol (Perforomist)
- Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
-
Knoxville, TennesseeUniversity of Tennessee Medical Center
Apr 26, 2021
Asthma Trial in Hackensack, New York (Fluticasone with salmeterol, Fluticasone HFA)
Completed
- Asthma
- Fluticasone with salmeterol
- +3 more
-
Hackensack, New Jersey
- +2 more
Oct 12, 2022
Bronchiectasis Adult Trial in São Paulo (Bronchodilator (Ipratropium and Fenoterol), Placebo)
Suspended
- Bronchiectasis Adult
- Bronchodilator (Ipratropium and Fenoterol)
- Placebo
-
São Paulo, Brazil
- +2 more
Jan 7, 2022
COPD, COPD Trial in Wellington (Placebo, TD-4208 700 µg, TD-4208 350 µg)
Completed
- Chronic Obstructive Pulmonary Disease, COPD
- Placebo
- +3 more
-
Wellington, New ZealandP3 Research
Feb 22, 2022
Exercise Induced Laryngeal Obstruction (EILO) Trial in Bergen (Ipratropium bromide spray)
Completed
- Exercise Induced Laryngeal Obstruction (EILO)
- Ipratropium bromide spray
-
Bergen, NorwayHaukeland University Hospital
Nov 26, 2020
Pulmonary Disease, Chronic Obstructive Trial in New Zealand, Thailand, United Kingdom (400 microgrammes GSK961081, 1200
Completed
- Pulmonary Disease, Chronic Obstructive
- 400 microgrammes GSK961081
- 1200 microgrammes GSK961081
-
Wellington, New Zealand
- +3 more
Sep 28, 2021
COPD Trial in Australia, New Zealand, United States (TV48108, Placebo)
Terminated
- Chronic Obstructive Pulmonary Disease
- TV48108
- Placebo
-
Medford, Oregon
- +6 more
Nov 6, 2021
Bronchospasm, Exercise-Induced Trial in San Francisco (ipratropium bromide, Placebo)
Completed
- Bronchospasm, Exercise-Induced
- ipratropium bromide
- Placebo
-
San Francisco, CaliforniaUniversity of California, San Francisco
May 20, 2020
COPD (COPD Trial in Australia, New Zealand, United States (TV46017, Placebo)
Terminated
- Chronic Obstructive Pulmonary Disease (COPD
- TV46017
- Placebo
-
Saint Louis, Missouri
- +6 more
Nov 5, 2021
Asthma, Depression, Childhood Asthma Trial in Buffalo (Ipratropium Bromide)
Completed
- Asthma
- +2 more
- Ipratropium Bromide
-
Buffalo, New YorkWomen and Children's Hospital of Buffalo
Nov 3, 2020
Acute Bronchitis Trial in Spain (drug, dietary supplement, other)
Recruiting
- Acute Bronchitis
- Dextromethorphan 15 milligrams
- +3 more
-
Badalona, Catalonia, Spain
- +11 more
Aug 30, 2021
Asthma Trial in Saskatoon (Ipratropium Metered Dose Inhaler, metered dose inhaler)
Completed
- Asthma
- Ipratropium Metered Dose Inhaler
- placebo metered dose inhaler
-
Saskatoon, Saskatchewan, CanadaUniversity of Saskatchewan
Mar 25, 2020
Pulmonary Disease, Chronic Obstructive Trial in United States (Budesonide, budesonide/formoterol, Ipratropium/albuterol)
Completed
- Pulmonary Disease, Chronic Obstructive
- Budesonide
- +2 more
-
Birmingham, Alabama
- +6 more
Jan 15, 2021
Asthma Trial (Nebulized Magnesium Sulfate, Nebulized normal saline)
Withdrawn
- Asthma
- Nebulized Magnesium Sulfate
- Nebulized normal saline
- (no location specified)
Sep 4, 2020
Asthma Trial in Nashville (AccuPAP, Albuterol and Ipratropium Continuous Nebulizer)
Withdrawn
- Asthma
- AccuPAP
- Albuterol and Ipratropium Continuous Nebulizer
-
Nashville, TennesseeVanderbilt University Medical Center Monroe Carell Jr. Childrens
Nov 11, 2020
Pulmonary Arterial Hypertension Trial (Nebulized ipratropium bromide, Nebulized combination ipratropium bromide with salbutamol,
Withdrawn
- Pulmonary Arterial Hypertension
- Nebulized ipratropium bromide
- +2 more
- (no location specified)
Jan 27, 2020
Shortness of Breath, Asthma in Children, Epinephrine Causing Adverse Effects in Therapeutic Use Trial (nebulized epinephrine,
Not yet recruiting
- Shortness of Breath
- +3 more
- nebulized epinephrine
- Normal saline
- (no location specified)
Dec 19, 2022